IRVINE, Calif., Feb. 1 -- Edwards Lifesciences Corporation (NYSE:EW), a world leader in products and technologies to treat advanced cardiovascular disease, is scheduled to participate in the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference at the Grand Hyatt Hotel in New York on Thursday, February 7, 2008.
Thomas M. Abate, Edwards Lifesciences' corporate vice president, chief financial officer & treasurer, is scheduled to speak to conference attendees at 11:00 a.m. ET.
A live webcast of the presentation will be available to all interested parties on the Edwards Lifesciences investor relations website at www.edwards.com/InvestorRelations/EventCalendar.htm. An archived version of the webcast will be available later that day on the Edwards investor relations website in the News and Events section.
About Edwards Lifesciences
Edwards Lifesciences, a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, vascular disease and critical care technologies. The company's global brands, which are sold in approximately 100 countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at http://www.edwards.com/.
Source: Edwards Lifesciences Corporation
CONTACT: media, Amanda Fowler, +1-949-250-5070, or investors, David K. Erickson, +1-949-250-6826, both of Edwards Lifesciences Corporation
Web site: http://www.edwards.com/